Endocrine Insider
October 28, 2009

(See Full Issue)

Last week, The Endocrine Society's Council approved the Society's most recent clinical guideline, Congenital Adrenal Hyperplasia (CAH) Due to Steroid 21-hydroxylase Deficiency. The guideline was developed by a task force of content experts chaired by Phyllis W Speiser, MD.

Co-sponsored by the American Academy of Pediatrics, Androgen Excess and PCOS Society, CARES Foundation, European Society of Endocrinology, European Society for Paediatric Endocrinology, Lawson Wilkins Pediatric Endocrine Society, and the Society of Pediatric Urology, the guideline addresses newborn screening, prenatal treatment, diagnosis after infancy, medical treatment of CAH in growing patients, treatment of NCCAH, complications of CAH, feminizing surgery, experimental treatments, and CAH in adulthood.  The guideline will be submitted for publication in the Journal of Clinical Endocrinology and Metabolism.

The Society’s Council also approved a revised version of The Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes guideline. This guideline was originally published in the June 2006 issue of the Journal of Clinical Endocrinology & Metabolism. According to Society policy, all guidelines will be evaluated three years after publication to determine if revisions or updates are needed. The task force, led by Shalender Bhasin, MD, reviewed recent developments in the field and determined that a few recommendations should be changed. A summary of the revisions will be included as a memo at the beginning of a future edition of the guideline.

All published Society clinical practice guidelines are available at http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm.

The Society has eight other guidelines nearing completion and coming soon. Please contact the Society's Government & Public Affairs department at govt-prof@endo-society.org for more information.